- Home
- LDI vs CRGX Comparison
LDI vs CRGX Comparison
Compare LDI & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- CRGX
- Stock Information
- Founded
- LDI 2010
- CRGX 2021
- Country
- LDI United States
- CRGX United States
- Employees
- LDI N/A
- CRGX N/A
- Industry
- LDI Finance: Consumer Services
- CRGX
- Sector
- LDI Finance
- CRGX
- Exchange
- LDI Nasdaq
- CRGX Nasdaq
- Market Cap
- LDI 221.2M
- CRGX 190.0M
- IPO Year
- LDI 2021
- CRGX 2023
- Fundamental
- Price
- LDI $1.40
- CRGX $4.27
- Analyst Decision
- LDI Sell
- CRGX Hold
- Analyst Count
- LDI 3
- CRGX 7
- Target Price
- LDI $1.98
- CRGX $4.67
- AVG Volume (30 Days)
- LDI 673.5K
- CRGX 663.4K
- Earning Date
- LDI 08-05-2025
- CRGX 08-11-2025
- Dividend Yield
- LDI N/A
- CRGX N/A
- EPS Growth
- LDI N/A
- CRGX N/A
- EPS
- LDI N/A
- CRGX N/A
- Revenue
- LDI $1,090,719,000.00
- CRGX N/A
- Revenue This Year
- LDI $28.75
- CRGX $58.18
- Revenue Next Year
- LDI $15.05
- CRGX N/A
- P/E Ratio
- LDI N/A
- CRGX N/A
- Revenue Growth
- LDI 21.07
- CRGX N/A
- 52 Week Low
- LDI $1.01
- CRGX $3.00
- 52 Week High
- LDI $3.23
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- LDI 56.36
- CRGX 45.02
- Support Level
- LDI $1.32
- CRGX $4.33
- Resistance Level
- LDI $1.47
- CRGX $4.48
- Average True Range (ATR)
- LDI 0.10
- CRGX 0.19
- MACD
- LDI 0.01
- CRGX -0.02
- Stochastic Oscillator
- LDI 58.33
- CRGX 21.14
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.